Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy
about
The structural biology of oestrogen metabolismInsights in 17beta-HSD1 enzyme kinetics and ligand binding by dynamic motion investigationHydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1)Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers.Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors.Aromatase, estrone sulfatase, and 17β-hydroxysteroid dehydrogenase: structure-function studies and inhibitor development.Human hydroxysteroid dehydrogenases and pre-receptor regulation: insights into inhibitor design and evaluation.Crucial Role of 3-Bromoethyl in Removing the Estrogenic Activity of 17β-HSD1 Inhibitor 16β-(m-Carbamoylbenzyl)estradiol.Sex steroid hormones in pairs of tumor and serum from breast cancer patients and pathobiological role of androstene-3β, 17β-diol.Interference of Paraben Compounds with Estrogen Metabolism by Inhibition of 17β-Hydroxysteroid Dehydrogenases.Design and synthesis of substrate mimetics based on an indole scaffold: potential inhibitors of 17β-HSD type 1.Synthesis and structure-activity relationships of 2- and/or 4-halogenated 13β- and 13α-estrone derivatives as enzyme inhibitors of estrogen biosynthesis
P2860
Q27009283-8B360156-A7BA-477E-8D7D-94BABC2717C2Q27322084-ED130735-F11B-467F-B0EC-ECCB5F6C9CBAQ28478724-E3635027-09CF-4666-91ED-32118DD9ABC3Q30847424-B4AF9D36-9B26-45F7-A65D-BE28E211E70CQ33809605-8493BE6C-CD9D-4A93-B22C-80B03225B4B7Q33953050-0C4745F8-676F-4F53-BD3D-84E90469444CQ34561176-FD477E79-270B-4C0E-94AD-4B20EB739E6CQ35013689-458CF2DC-1D18-4326-A2FC-ED667428485EQ38449142-E4F45A1C-BD1A-48B5-B89D-E1DBF13774D2Q39517276-59CF383E-6CA0-4C5E-8B51-C08E381EC38BQ41660311-AA7E0B6A-9E23-423E-ACF6-F604B9F6C227Q54364371-6724C3B7-8C00-44AC-84ED-40E7A01DBC37Q58718708-9B26AB1A-15B2-4A34-BF2A-426F8CD98B29
P2860
Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Binary and ternary crystal str ...... ound for breast cancer therapy
@ast
Binary and ternary crystal str ...... ound for breast cancer therapy
@en
Binary and ternary crystal str ...... ound for breast cancer therapy
@nl
type
label
Binary and ternary crystal str ...... ound for breast cancer therapy
@ast
Binary and ternary crystal str ...... ound for breast cancer therapy
@en
Binary and ternary crystal str ...... ound for breast cancer therapy
@nl
prefLabel
Binary and ternary crystal str ...... ound for breast cancer therapy
@ast
Binary and ternary crystal str ...... ound for breast cancer therapy
@en
Binary and ternary crystal str ...... ound for breast cancer therapy
@nl
P2093
P2860
P356
P1433
P1476
Binary and ternary crystal str ...... ound for breast cancer therapy
@en
P2093
Christine Cadot
Dao-Wei Zhu
Diane Fournier
Donald Poirier
Mausumi Mazumdar
P2860
P304
P356
10.1042/BJ20091020
P407
P577
2009-12-10T00:00:00Z